Accurate control of tissue-specific gene expression plays a pivotal role in heart development, but few cardiac transcriptional enhancers have thus far been identified. Extreme noncoding-sequence conservation has successfully predicted enhancers that are active in many tissues but has failed to identify substantial numbers of heart-specific enhancers. Here, we used ChIP-Seq with the enhancerassociated protein p300 from mouse embryonic day 11.5 heart tissue to identify over 3,000 candidate heart enhancers genome wide. Compared to enhancers active in other tissues we studied at this time point, most candidate heart enhancers were less deeply conserved in vertebrate evolution. Nevertheless, transgenic mouse assays of 130 candidate regions revealed that most function reproducibly as enhancers active in the heart, irrespective of their degree of evolutionary constraint. These results provide evidence for a large population of poorly conserved heart enhancers and suggest that the evolutionary conservation of embryonic enhancers can vary depending on tissue type.
Heart disease is a leading cause of mortality in both infants and adults 1, 2 . Despite extensive screening of protein-coding regions, the genetic basis of many cardiac defects is unknown [3] [4] [5] . Although variants of gene regulatory sequences have been previously suggested to play a role in heart disease 6 , these variants' contributions have been difficult to evaluate because the genomic locations and activity patterns of regulatory sequences active in the heart remain largely obscure. Among the different types of regulatory sequence, transcriptional enhancers are particularly challenging to identify, as they can be located at large genomic distances from the genes they regulate 7 . Though extreme evolutionary sequence conservation has been a valuable tool for the identification of developmental enhancers in general [8] [9] [10] [11] [12] [13] [14] , relatively few heart enhancers have been identified by this approach. In the largest existing datasets of in vivo embryonic enhancers identified through extreme sequence conservation 13, 14 , fewer than 2% of tested sequences were found to be heart enhancers, as compared to sequences found for forebrain, midbrain and limb enhancers (at 16%, 14% and 5%, respectively). This raises the possibilities that at this time point in embryonic development, there are either fewer enhancers active in heart than in other tissues or the conservation properties of heart enhancers differ from those of other tissues, rendering them unidentifiable by comparative genomic approaches. To resolve this issue, we sought an alternative genomic approach for identifying heart enhancers that is independent of the requirement for evolutionary DNA constraint.
The transcriptional coactivator protein p300 is expressed nearly ubiquitously in mouse embryogenesis 15 and can bind to a wide spectrum of active tissue-specific enhancers. Taking advantage of these properties, chromatin immunoprecipitation with p300 directly from animal tissues coupled with massively parallel sequencing (ChIP-Seq) can accurately predict the genomic location and tissue specificity of active developmental enhancers [16] [17] [18] [19] . To obtain an initial genomewide set of candidate enhancer sequences active in the heart, we performed p300 ChIP-Seq on heart tissue from approximately 270 mouse embryos at embryonic day 11.5 (E11.5). Enrichment analysis 20 of this dataset identified 3,597 regions that do not overlap known promoters but that were significantly enriched in p300 binding (using an estimated false discovery rate threshold of 1%) and were therefore considered as candidate heart enhancers. For comparison across different embryonic tissues, we applied the same ChIP-Seq analysis approach to samples from E11.5 forebrain, midbrain and limbs and identified 2,759, 2,786 and 3,839 p300-enriched regions in these tissues, respectively (see Online Methods and Supplementary Tables 1-4) . The vast majority (84%) of p300 peaks in heart tissue do not overlap p300 peaks found in any of the other three tissues examined. These results indicate that p300 binding in the developing heart identifies a subset of noncoding regions that are distinct from putative enhancers active in other embryonic structures.
To evaluate potential differences in the conservation properties of enhancers between tissues, we compared the evolutionary conservation depth of candidate heart and forebrain enhancers (the two tissues for which conservation-based predictions were least and most l e t t e r s successful, respectively; see Online Methods). Most (65%) predicted heart enhancers were detectably conserved only among placental mammals, whereas the majority (56%) of predicted forebrain enhancers were conserved between mammals and birds (Fig. 1a) . Using the median divergence time of species with detectable conservation as an approximate measure of evolutionary conservation depth, the predicted forebrain enhancers were almost three times as deeply conserved as predicted heart enhancers (median divergence times of 310 million years and 105 million years, respectively; Fig. 1a) . The difference between the two tissues is particularly pronounced at the extremes of the conservation spectrum. Heart enhancers are ninefold more abundant than forebrain enhancers among sequences conserved only within rodents, whereas predicted forebrain enhancers are seven times more frequent than heart enhancers among sequences conserved between mammals and fish (Fig. 1a) . Predicted limb and midbrain enhancers exhibited an intermediate degree of evolutionary conservation compared with heart and forebrain enhancers ( Supplementary  Fig. 1 ), which is consistent with the frequency of enhancers in these tissues in comparative genomic datasets 13, 14 . Notably, there is substantial overlap between the conservation profiles of heart enhancers and matched random genomic regions ( Fig. 1a and Supplementary  Fig. 2 ), suggesting that in contrast to forebrain enhancers, a sizable proportion of heart enhancers active at this time point cannot be confidently distinguished from surrounding genomic sequence by evolutionary conservation alone.
To further evaluate differences in conservation properties, we compared the evolutionary constraint of enhancers from all four types of tissue using pre-computed evolutionary constraint scores (phastCons 21 scores) generated from multivertebrate genome alignments 22 .
Overall, only 6% of candidate heart enhancers overlapped genome regions that were under extremely high constraint (score >600) as compared to 44%, 39% and 30% of candidate forebrain, midbrain and limb enhancers, respectively (P < 10 −22 according to Fisher's exact test; Fig. 1b) . Conversely, the fraction of candidate heart enhancers that did not overlap detectably constrained sequences (24%) was four-to sevenfold greater than those for candidate enhancers from other studied tissues (P < 10 −14 according to Fisher's exact test; Fig. 1c, Supplementary Table 5 and Supplementary Fig. 3) . Notably, these observations were robustly maintained when we determined sequence constraint from subsets of vertebrate species covering shorter evolutionary distances (Supplementary Fig. 4a-d ) and when we used relaxed stringency thresholds for defining p300 peaks ( Supplementary Fig. 4e-h ). Taken together, these results show pronounced differences in the degree of evolutionary sequence constraint of p300-binding regions across tissues, with candidate heart enhancers being under weaker constraint than enhancers active in other tissues. This observation provides a plausible explanation for the poor performance of extreme sequence conservation in identification of heart enhancers at this time point and suggests that p300 binding might identify a sizable population of weakly conserved heart enhancers that are likely to be missed by existing comparative genomic approaches.
To assess the in vivo activity of p300-based predictions of heart enhancers, we tested 130 candidate heart enhancers in a transgenic mouse enhancer assay 13, 23 (Supplementary Fig. 5 ). In total, we found 97 sequences (75%) to be reproducible tissue-specific enhancers in E11.5 embryos (the p300 ChIP-seq time point), of which the vast majority (81/97, or 84%) were active in the developing heart Figure 1 Weak evolutionary conservation of candidate heart enhancers identified by p300 binding in embryos at E11.5. (a) Comparison of the evolutionary conservation properties of the top 500 ranked candidate heart and forebrain enhancers identified through p300 binding in E11.5 tissues (Online Methods). Conservation depth of enhancers was defined as the estimated divergence time from mice of the most distantly related species with aligned genomic sequence 22, 36 . The median (vertical bar), 25th-75th percentile (horizontal bar) and 10th-90th percentile (horizontal line) intervals of conservation depth are shown for forebrain enhancers (blue), heart enhancers (red) and sequence property matched genomic background (gray). The horizontal axis represents the mouse evolutionary lineage, with the vertical dashed lines indicating the estimated divergence times [37] [38] [39] of species or groups of species with sequenced genomes included in the analysis. For each interval on the mouse lineage, the bar chart shows the ratio of forebrain enhancers to heart enhancers among enhancers that are maximally conserved in that interval. (b,c) Onekilobase regions flanking p300 peaks from each tissue were assigned the score of the most highly constrained overlapping vertebrate phastCons 21 element in the mouse genome. (b) The fraction of candidate enhancers that were under strong evolutionary constraint (score > 600). (c) The fraction of candidate enhancers that were under no detectable constraint (no overlapping vertebrate constrained element). Error bars represent 95% binomial proportion confidence interval. *P < 10 -14 according to a one-tailed Fisher's exact test. Table 6 ). This represents a greater than 29-fold increase in specificity for heart enhancers over previous approaches based on extreme evolutionary constraint, in which only 8 out of 282 (3%) sequences that were confirmed to be enhancers in the same transgenic assay were also active in the heart (P < 10 −55 according to Fisher's exact test; Fig. 2a) . Notably, we found no significant difference in the frequency of positive heart enhancers among the highly conserved sequences (19/31, or 61%) compared with the sequences that overlapped no conservation (16/30, or 53%; P > 0.1 according to Fisher's exact test). These results suggest that p300 is an accurate predictor of enhancer activity independent of sequence conservation, and they confirm the in vivo activity of weakly and apparently nonconstrained heart enhancers (Fig. 2b) .
The heart encompasses several anatomical subregions and cell types at E11.5, which include the precursor structures of the definitive functional compartments of the heart (atria and ventricles) as well as transient structures and cell populations that have critical functions in heart development and disease 24 . To examine the spatial diversity of the identified heart enhancers, we annotated reproducible reporter staining patterns within whole-mount stained embryos (Fig. 3 , lateral views and Supplementary Table 7) . Essentially all anatomical subregions were reproducibly targeted by at least one of the identified in vivo enhancers (Fig. 3a,b -e, frontal views and Supplementary Table 7) . To characterize expression patterns in more detail, we examined transverse sections of hearts from representative embryos, which revealed examples of enhancers with activity in each of the major tissue types and discrete lineages within the developing heart (Fig. 3b-e , transverse sections and Supplementary Table 7 ). The observed patterns included regions of the developing heart such as the interventricular septum, which is a common site of structural defects in cases of congenital heart disease 2 (Fig. 3e) . These results suggest that this enhancer identification approach has the potential to uncover regulatory regions that have relevance to human disease. Both strongly and weakly constrained enhancer sequences exhibited highly reproducible staining in the heart, and we saw no significant correlation between the reproducibility of expression patterns and their respective sequence constraint (Supplementary Fig. 6) . Notably, the enhancers identified in these studies exhibited highly restricted expression patterns, with 51/81 (63%) of enhancers driving reproducible reporter gene expression exclusively in the developing heart (Supplementary Tables 6 and 7). These data indicate that p300 binding identifies enhancers with activity throughout the developing heart with no detectable regional or tissue-specific bias.
Several of the enhancers validated through our in vivo studies are located near genes with well-described roles in heart development or function (Supplementary Fig. 7 
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(a) Comparison of the frequency of positive heart enhancers among previously tested sequences predicted on the basis of extreme evolutionary constraint 13, 14 and sequences predicted by heart p300 ChIP-seq. *P < 10 −8 according to a one-tailed Fisher's exact test. (b) Frequency of positive heart enhancers among tested sequences exhibiting different degrees of evolutionary sequence constraint (highly constrained, score >450; moderately constrained, score 350-450; weakly constrained, score <350; no detectable constraint, no overlapping constrained element). Error bars represent 95% binomial proportion confidence interval. n.s., not significant (P > 0.05 for all pair-wise comparisons using a two-tailed Fisher's exact test). 
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l e t t e r s activity patterns consistent with the expression of those genes (Supplementary Note). To assess a possible global enrichment of predicted heart enhancers near genes implicated in heart development, we determined the frequency of heart p300 peaks near genes annotated with the gene ontology 25 (GO) term 'heart development' and near genes that are expressed during heart development 26 . We found a more than threefold enrichment in heart p300 peaks within 100 kb of the transcript start sites (excluding the promoter region) of known 'heart-development' genes (P < 10 −5 according to Fisher's exact test), a number that increased to over 14-fold enrichment for peaks within 10 kb of the transcript start sites of these genes (P < 10 −4 according to Fisher's exact test; Fig. 4a) . Similarly, there was a more than 13-fold enrichment in heart p300 peaks within 10 kb of the transcript start sites of the 1,000 genes most highly expressed in embryonic heart (P < 10 −4 according to Fisher's exact test; Fig. 4b ), and we also observed enrichment near genes that are specifically overexpressed in the heart as compared with the whole embryo ( Supplementary  Fig. 8) . As negative controls, we observed no pronounced enrichment of forebrain p300 binding sites near heart genes (P > 0.1 according to Fisher's exact test; Fig. 4a,b) , and we observed no enrichment of p300 binding sites in other tissues near heart genes ( Supplementary  Figs. 8-10 ). In addition to these findings, candidate heart enhancers were enriched in binding sites for transcription factors with known roles in heart gene regulatory networks (Supplementary Fig. 11 ). Together, these results support a global role for p300-associated candidate heart enhancers in tissue-specific transcriptional activation of neighboring genes during heart development, and they provide further evidence that a substantial proportion of the heart-specific p300-binding sites identified in this study are bona fide heart enhancers. In summary, we have identified and functionally validated a large population of enhancers active in the E11.5 heart and found these enhancers to be under substantially weaker evolutionary constraint than enhancers active in other anatomical regions at the same developmental stage, despite their association with the same transcriptional coactivator protein, p300. Although the causes and biological relevance of these constraint differences remain to be determined, the observation may be considered unexpected given the evolutionary antiquity of the heart and the genetic pathways that control its development 27 .
The question of whether sequence constraint is a general hallmark of gene regulatory elements has important implications for locating their position within the genome, as well as for understanding their function and evolutionary origin 28 . Cell culture-derived transcription factor binding data, along with comparative genomic analyses of isolated in vivo characterized enhancers, have provided first indications that not all functional noncoding sequences are detectably constrained [29] [30] [31] [32] [33] . However, the genomic scale at which such putatively functional nonconstrained elements have specific and reproducible in vivo activities has remained elusive because experimental data were available only for selected loci 34 . Our results suggest that, at least for the time point studied, existing conservation-based measures underestimate the proportion of the genome that has regulatory functions in vivo. This notion is further supported by results from a recent study combining evolutionary constraint with sequence motif analysis for genome-wide prediction of heart enhancers, which did not identify many of the heart enhancers validated in vivo in the present study 35 (Supplementary Table 8 and Supplementary Note). These results emphasize the importance of experimental approaches for the unbiased annotation of functional elements in the genome. Based on our transgenic assays, a considerable proportion of the thousands of genomic regions predicted by this study are likely to be true heart enhancers. The comprehensive genome-wide set of candidate sequences provided through these studies will facilitate the exploration of regulatory elements in cardiac development and disease.
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(a-b) Enrichment of heart and forebrain p300 peaks in the proximity of transcript start sites of heart development genes (GO:0007507) (a) and the 1,000 most highly expressed genes in E11.5 mouse heart 26 (b). Fold enrichment was determined by comparing the observed frequency of peaks up to 500 kb away from transcript start sites to an equal number of randomized positions genomewide. For each tissue, only the 500 most significant p300 peaks were considered. Bold lines represent average fold enrichment; error bars indicate confidence intervals for the fifth and ninetyfifth percentiles (Online Methods).
oNLINE METHodS
ChIP sequencing from mouse embryonic tissues. Embryonic heart and midbrain tissues were isolated from approximately 270 CD-1 strain embryos at E11.5 by microdissection in cold PBS. Tissue samples were processed for ChIP and DNA sequencing as described previously 19 . Briefly, tissues were cross-linked in formaldehyde and cells were dissociated in a glass Dounce homogenizer. Chromatin isolation, sonication and immunoprecipitation using an anti-p300 antibody (rabbit polyclonal anti-p300; SC-585, Santa Cruz Biotechnology) were performed as previously described 41, 42 . Approximately 0.1 ng of each ChIP DNA sample was sheared by sonication, end-repaired, ligated to sequencing adapters and amplified by emulsion PCR for 40 cycles 43 . Amplified ChIP DNA was sequenced for 36 cycles on the Illumina Genome Analyzer II as described previously 19 . P300 ChIP-seq data from E11.5 mouse forebrain and limb samples were previously published 19 but were reanalyzed for this study using the approach outlined below.
Processing of ChIP-sequence data. Unfiltered 36 bp sequence reads were aligned to the mouse reference genome (NCBI build 37, mm9) using BLAT as described previously 19 . P300-enriched regions were identified using QuEST (version 2.3) 20 with the following parameters: bandwidth = 60 bp, region_ size = 600 bp, ChIP enrichment = 10, ChIP extension enrichment = 3 and no QuEST_align_RX_noIP file. Peaks with a regional q value of less than 2 (equivalent to a Poisson-estimated false discovery rate of less than or equal to 1%) were removed. Peaks mapping to unassembled chromosomal contigs, centromeric regions, telomeric regions, segmental duplications, peaks consisting of >70% repeat sequence, peaks coinciding with enriched regions from an E11.5 forebrain control sample (input DNA) and peaks where >20% contributing reads originated in a self-chain alignment were removed as likely artifacts.
To exclude likely promoter sequences, we removed all p300-bound regions for which the distance from the peak maximum to the nearest transcript start site (from UCSC-known genes 22 ) was less than 1 kb. The remaining peaks represented candidate distant-acting enhancers with activity in specific tissues. For consistent methodology and to allow relative ranking of peaks within datasets, we reanalyzed previously generated p300 ChIP-Seq data from forebrain and limb samples 19 according to the scheme described above. Peak calling using QuEST was highly consistent with the previously used approach. At least 87% of forebrain or limb p300 peaks identified previously, including all previously in vivo tested sequences, overlapped a QuEST peak in the current analysis. Conversely, at least 95% of the top 1,000 forebrain or limb p300 peaks identified using QuEST were identified in the previous analyses (data not shown).
Computational analyses of candidate distant-acting enhancers. To most accurately identify and compare properties of candidate distant-acting enhancer datasets, computational analyses were initially performed on the top 500 high confidence candidate distant-acting enhancers from each tissue. An equal number of peaks were selected from each tissue to enable statistically straightforward comparisons. For analyses of constraint and conservation, the top 500 candidate distant-acting enhancers were selected from p300 peaks which were located more than 5 kb from the nearest transcript start sites in order to ensure maximum filtering of promoter-proximal regions which were likely to contain conserved functional sequences other than enhancers (for example, PolII binding sites and unannotated exons). For conservation depth analyses, multiple sequence alignments for the 100-bp region centered on the peak maximum of selected regions were extracted from pre-computed 30-way alignments to the mouse genome 22, 36 . Maximum conservation depth was evaluated from the most distantly related species with at least 50% of the bases aligned to the mouse reference across this region, and timescales were obtained from current estimates of divergence times among vertebrates [37] [38] [39] . To evaluate the conservation properties of the genome background, we used 100-bp regions centered on the midpoint of 10,000 random regions in the genome with matched size distribution and sequence mappability and that had been subjected to the same filtering procedure applied to p300 peaks. For sequence constraint analyses, selected regions were assigned the score of the highest-scoring phastCons element 21 overlapping the 1-kb genomic interval centered on the peak maximum. The same approach was used for analyses using either the top 500 scoring or all candidate distantacting enhancers (including elements up to 1 kb from the nearest transcript start site) and analyses in which phastCons conservation scores were derived from placental mammal or euarchontoglire multiple sequence alignments. Regions with no overlapping phastCons elements were referred to as 'not detectably constrained' (Supplementary Fig. 2) . Enrichment of candidate enhancers near genes involved in heart development was determined using the top 500 scoring p300 ChIP-Seq peaks greater than 1 kb from the nearest transcript start site from each tissue. For each dataset, peak randomizations were generated by moving each peak to a random location on the same chromosome, excluding regions that were less than 50% mappable (as determined by BLAT) or that failed the peak filtering procedure described above. Enrichment of p300 peaks near 203 'heart development' genes (GO:0007507) was calculated as the average, from 1,000 peak randomizations, of the ratio of p300 peaks to randomized peaks at defined distances from the nearest heart gene transcript start site. To determine the specificity of enrichment in the vicinity of heart genes, 1,000 control datasets of 'non-heart genes' were assembled by randomly selecting 203 genes (using UCSC-known genes) that were not annotated with the 'heart development' GO term. Enrichment near non-heart genes was calculated as the average, from 1,000 total randomizations of peaks and control genes, of the ratio of p300 peaks to randomized peaks at defined distances from the nearest nonheart gene transcript start site. For analysis of candidate enhancers near heartexpressed genes, the 1,000 most highly expressed and the 1,000 least expressed genes were identified from publicly available E11.5 mouse heart expression data (GEO Series GSE1479, samples GSM25153-GSM25155) 26 . For analysis of candidate enhancers near heart-specific genes (Supplementary Fig. 8 ), heart over-expressed and heart under-expressed genes were identified by comparison with E11.5 whole embryo expression data 19 . Heart overexpressed genes were those with an expression level of >100 in E11.5 hearts and at least fivefold higher expression than in whole embryo. Conversely, heart under-expressed genes were those with an expression level of >100 in E11.5 whole embryo and at least fivefold higher expression in the embryo compared with the heart. Enrichment of p300 peaks near heart-expressed and not expressed gene sets was calculated as the average, from 1,000 peak randomizations, of the ratio of p300 peaks to randomized peaks at defined distances from the nearest transcript start site. The same approach was used for analyses of all p300 peaks from each tissue, and this analysis showed similar results ( Supplementary  Figs. 8c,d and 9c,d) .
Transcription factor binding site analysis of the top 500 p300 peaks from the heart and forebrain was performed by first dividing each dataset into equally sized bins containing the 250 most conserved and the 250 least conserved candidate enhancers. For each dataset, a 200-bp region centered on the position of maximum p300 coverage was searched against motifs in the JASPAR database 44 of non-redundant vertebrate transcription factor binding profiles using MAST 45 . Only binding sites that were present in at least 15 (>5%) sequences from at least one dataset were retained for further analysis. Transcription factor binding site counts were then converted to fold enrichment in comparisons between forebrain and heart datasets with the same conservation score.
Transgenic mouse enhancer assay. Regions for in vivo testing were primarily selected to be representative of the sequence constraint properties (vertebrate phastCons scores) of all 3,597 candidate distant-acting heart enhancers identified through p300 binding. Peaks were otherwise selected based on rank peak score and were moderately biased toward sequences greater than 5 kb from the nearest transcript start site (Supplementary Fig. 3 ). Enhancer candidate regions consisting of ~2 kb of mouse genomic DNA flanking the p300 peak were amplified by PCR from mouse genomic DNA (Clontech) and cloned into the Hsp68-promoter-LacZ reporter vector as previously described 9, 23 . Genomic coordinates of amplified regions are reported in Supplementary  Table 5 . Transgenic mouse embryos were generated by pronuclear injection and F0 embryos were collected at E11.5 and stained for β-galactosidase activity with 5-bromo-4-chloro-3-indolyl β-d-galactopyranoside (X-Gal) as previously described 9 . Only patterns that were observed in at least three different embryos resulting from independent transgenic integration events of the same construct were considered reproducible. For all confirmed reproducible heart enhancers, close-up images of the heart were taken of at least one representative embryo, and expression patterns were classified according to X-Gal staining in broadly defined anatomical regions. Selected elements were subject to sectioning (Supplementary Table 7) . For detailed section analyses, embryos were collected at E11.5, fixed in 4% paraformaldehyde and stained with X-Gal overnight. X-Gal-stained embryos were then embedded in paraffin using standard methods. Transverse sections were cut at a thickness of 8 μm, and sections were counterstained with neutral fast red for visualization of embryonic structures by light microscopy and photographed.
Animal work. All animal work was performed in accordance with protocols reviewed and approved by the Lawrence Berkeley National Laboratory Animal Welfare and Research Committee.
